US20040072735A1 - Methods of inducing terminal differentiation - Google Patents
Methods of inducing terminal differentiation Download PDFInfo
- Publication number
- US20040072735A1 US20040072735A1 US10/379,149 US37914903A US2004072735A1 US 20040072735 A1 US20040072735 A1 US 20040072735A1 US 37914903 A US37914903 A US 37914903A US 2004072735 A1 US2004072735 A1 US 2004072735A1
- Authority
- US
- United States
- Prior art keywords
- subject
- composition
- saha
- hdac inhibitor
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [2*]C(=O)CC(=O)N([3*])[4*] Chemical compound [2*]C(=O)CC(=O)N([3*])[4*] 0.000 description 49
- WAEXFXRVDQXREF-UHFFFAOYSA-N [H]N(C(=O)CCCCCCC(=O)NO)C1=CC=CC=C1 Chemical compound [H]N(C(=O)CCCCCCC(=O)NO)C1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 8
- PTJGLFIIZFVFJV-UHFFFAOYSA-N [H]N(C(=O)CCCCCCC(=O)NO)C1=CC=CN=C1 Chemical compound [H]N(C(=O)CCCCCCC(=O)NO)C1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 description 8
- YFQFXTMNTVGXCB-UHFFFAOYSA-N CC1=CC2=CC=CC=C2C=C1.CC1=CC2=CC=CC=C2C=N1.CC1=CC2=CC=CC=C2N=C1.CC1=CC2=CC=CN=C2C=C1.CC1=CC2=CC=NC=C2C=C1.CC1=CC2=CN=CC=C2C=C1.CC1=CC2=NC=CC=C2C=C1.CC1=CC=CC2=CC=CC=C12.CC1=CC=CC2=CC=CN=C12.CC1=CC=CC2=CC=NC=C12.CC1=CC=CC2=CN=CC=C12.CC1=CC=CC2=NC=CC=C12.CC1=CC=NC2=CC=CC=C12.CC1=CN=CC2=CC=CC=C12.CC1=NC2=CC=CC=C2C=C1.CC1=NC=CC2=CC=CC=C21 Chemical compound CC1=CC2=CC=CC=C2C=C1.CC1=CC2=CC=CC=C2C=N1.CC1=CC2=CC=CC=C2N=C1.CC1=CC2=CC=CN=C2C=C1.CC1=CC2=CC=NC=C2C=C1.CC1=CC2=CN=CC=C2C=C1.CC1=CC2=NC=CC=C2C=C1.CC1=CC=CC2=CC=CC=C12.CC1=CC=CC2=CC=CN=C12.CC1=CC=CC2=CC=NC=C12.CC1=CC=CC2=CN=CC=C12.CC1=CC=CC2=NC=CC=C12.CC1=CC=NC2=CC=CC=C12.CC1=CN=CC2=CC=CC=C12.CC1=NC2=CC=CC=C2C=C1.CC1=NC=CC2=CC=CC=C21 YFQFXTMNTVGXCB-UHFFFAOYSA-N 0.000 description 2
- YFXQTMCUHFROBC-UHFFFAOYSA-N CC1=CC2=NC=CC=C2C=C1.CC1=CC=CC2=CC=CN=C12.CC1=NC=NC2=NC=CN=C12.CC1CCCC2=CC=CC=C21.CN1C=NC2=CN=CN=C21 Chemical compound CC1=CC2=NC=CC=C2C=C1.CC1=CC=CC2=CC=CN=C12.CC1=NC=NC2=NC=CN=C12.CC1CCCC2=CC=CC=C21.CN1C=NC2=CN=CN=C21 YFXQTMCUHFROBC-UHFFFAOYSA-N 0.000 description 2
- BNYSWHSUCZNXLF-CCEZHUSRSA-N O=C(/C=C/C1=CC(C(C(=O)NC2=CC=CC3=C2N=CC=C3)C(=O)NC2=C3N=CC=CC3=CC=C2)=CC=C1)NO Chemical compound O=C(/C=C/C1=CC(C(C(=O)NC2=CC=CC3=C2N=CC=C3)C(=O)NC2=C3N=CC=CC3=CC=C2)=CC=C1)NO BNYSWHSUCZNXLF-CCEZHUSRSA-N 0.000 description 2
- UYWMXHFOTLWYES-UHFFFAOYSA-N CC(=O)C(C)CC(C)C(=O)[Y] Chemical compound CC(=O)C(C)CC(C)C(=O)[Y] UYWMXHFOTLWYES-UHFFFAOYSA-N 0.000 description 1
- LGZCCUCINVZAPB-UHFFFAOYSA-N CC(=O)CC(=O)NC(=O)C1=CC=C(C(=O)NC(=O)CC(=O)[Y])C=C1 Chemical compound CC(=O)CC(=O)NC(=O)C1=CC=C(C(=O)NC(=O)CC(=O)[Y])C=C1 LGZCCUCINVZAPB-UHFFFAOYSA-N 0.000 description 1
- DKKZLKLWLVCXEG-UHFFFAOYSA-N Cl.NO.[H]N(C(=O)CCCCCCC(=O)OC)C1=CC=CC=C1.[H]N(O)C(=O)CCCCCCC(=O)N([H])C1=CC=CC=C1 Chemical compound Cl.NO.[H]N(C(=O)CCCCCCC(=O)OC)C1=CC=CC=C1.[H]N(O)C(=O)CCCCCCC(=O)N([H])C1=CC=CC=C1 DKKZLKLWLVCXEG-UHFFFAOYSA-N 0.000 description 1
- SQGNVWSNUGLNRK-CCEZHUSRSA-N O=C(/C=C/C1=CC(C(C(=O)NC2=CC=CC=C2)C(=O)NC2=CC=CC=C2)=CC=C1)NO Chemical compound O=C(/C=C/C1=CC(C(C(=O)NC2=CC=CC=C2)C(=O)NC2=CC=CC=C2)=CC=C1)NO SQGNVWSNUGLNRK-CCEZHUSRSA-N 0.000 description 1
- OYKBQNOPCSXWBL-UHFFFAOYSA-N O=C(C=CC1=CC(C(=O)NO)=CC=C1)NO Chemical compound O=C(C=CC1=CC(C(=O)NO)=CC=C1)NO OYKBQNOPCSXWBL-UHFFFAOYSA-N 0.000 description 1
- DUDFEHXYDJDDTP-UHFFFAOYSA-N O=C(CC(C(=O)NC1=CC=C2N=CC=CC2=C1)C(=O)NC1=CC2=CC=CN=C2C=C1)NO Chemical compound O=C(CC(C(=O)NC1=CC=C2N=CC=CC2=C1)C(=O)NC1=CC2=CC=CN=C2C=C1)NO DUDFEHXYDJDDTP-UHFFFAOYSA-N 0.000 description 1
- RKEJMYPBGPJMKR-UHFFFAOYSA-N O=C(CC(C(=O)NC1=CC=CC2=C1N=CC=C2)(C(=O)NC1=C2N=CC=CC2=CC=C1)C1=CC=CC=C1)NO Chemical compound O=C(CC(C(=O)NC1=CC=CC2=C1N=CC=C2)(C(=O)NC1=C2N=CC=CC2=CC=C1)C1=CC=CC=C1)NO RKEJMYPBGPJMKR-UHFFFAOYSA-N 0.000 description 1
- SENSHQKVFOYBQN-UHFFFAOYSA-N O=C(CC(C(=O)NC1=CC=CC2=C1N=CC=C2)C(=O)NC1=C2N=CC=CC2=CC=C1)NO Chemical compound O=C(CC(C(=O)NC1=CC=CC2=C1N=CC=C2)C(=O)NC1=C2N=CC=CC2=CC=C1)NO SENSHQKVFOYBQN-UHFFFAOYSA-N 0.000 description 1
- YYHJQOYLXJKREY-UHFFFAOYSA-N O=C(CC(C(=O)NC1=CN=C2C=CC=CC2=C1)C(=O)NC1=CC2=CC=CC=C2N=C1)NO Chemical compound O=C(CC(C(=O)NC1=CN=C2C=CC=CC2=C1)C(=O)NC1=CC2=CC=CC=C2N=C1)NO YYHJQOYLXJKREY-UHFFFAOYSA-N 0.000 description 1
- HRSYWLWCWPPQTC-INIZCTEOSA-N O=C(C[C@H](NC(=O)C1=CC=CC=C1)C(=O)NC1=C2N=CC=CC2=CC=C1)NO Chemical compound O=C(C[C@H](NC(=O)C1=CC=CC=C1)C(=O)NC1=C2N=CC=CC2=CC=C1)NO HRSYWLWCWPPQTC-INIZCTEOSA-N 0.000 description 1
- BQKPTHHYCTZXQQ-KRWDZBQOSA-N O=C(C[C@H](NC(=O)C1=CC=CC=C1)C(=O)NC1=CC2=CC=CN=C2C=C1)NO Chemical compound O=C(C[C@H](NC(=O)C1=CC=CC=C1)C(=O)NC1=CC2=CC=CN=C2C=C1)NO BQKPTHHYCTZXQQ-KRWDZBQOSA-N 0.000 description 1
- GITUQMXYVXMMQE-AWEZNQCLSA-N O=C(C[C@H](NC(=O)C1=CC=CC=C1)C(=O)NC1=CC=CC=C1)NO Chemical compound O=C(C[C@H](NC(=O)C1=CC=CC=C1)C(=O)NC1=CC=CC=C1)NO GITUQMXYVXMMQE-AWEZNQCLSA-N 0.000 description 1
- YUTZZCNZNKBNQQ-ZDUSSCGKSA-N O=C(C[C@H](NC(=O)C1=CC=CN=C1)C(=O)NC1=CC=CC=C1)NO Chemical compound O=C(C[C@H](NC(=O)C1=CC=CN=C1)C(=O)NC1=CC=CC=C1)NO YUTZZCNZNKBNQQ-ZDUSSCGKSA-N 0.000 description 1
- RJSIDTDCYVJVIE-KRWDZBQOSA-N O=C(C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)NC1=C2N=CC=CC2=CC=C1)NO Chemical compound O=C(C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)NC1=C2N=CC=CC2=CC=C1)NO RJSIDTDCYVJVIE-KRWDZBQOSA-N 0.000 description 1
- SXUXGJCEDYWLDM-SFHVURJKSA-N O=C(C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)NC1=CC2=CC=CN=C2C=C1)NO Chemical compound O=C(C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)NC1=CC2=CC=CN=C2C=C1)NO SXUXGJCEDYWLDM-SFHVURJKSA-N 0.000 description 1
- UOQJIRZUUPHGMQ-HNNXBMFYSA-N O=C(C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)NC1=CC=CC=C1)NO Chemical compound O=C(C[C@H](NC(=O)OCC1=CC=CC=C1)C(=O)NC1=CC=CC=C1)NO UOQJIRZUUPHGMQ-HNNXBMFYSA-N 0.000 description 1
- CJNDVJIYUGLRMO-UHFFFAOYSA-N [H]N(C(=O)CC(=O)NO)C1=CC=CC=C1 Chemical compound [H]N(C(=O)CC(=O)NO)C1=CC=CC=C1 CJNDVJIYUGLRMO-UHFFFAOYSA-N 0.000 description 1
- UVYVSYPVDVIKCC-UHFFFAOYSA-N [H]N(C(=O)CCCCCCC(=O)NO)C1=CC=CC=N1 Chemical compound [H]N(C(=O)CCCCCCC(=O)NO)C1=CC=CC=N1 UVYVSYPVDVIKCC-UHFFFAOYSA-N 0.000 description 1
- RJMOPRKLNDSPIG-UHFFFAOYSA-N [H]N(C(=O)CCCCCCC(=O)NO)C1=CC=NC=C1 Chemical compound [H]N(C(=O)CCCCCCC(=O)NO)C1=CC=NC=C1 RJMOPRKLNDSPIG-UHFFFAOYSA-N 0.000 description 1
- IJPNIXXQNJPMCA-UHFFFAOYSA-N [H]N(C(=O)CCCCCCC(=O)O)C1=CC=CC=C1.[H]N(C(=O)CCCCCCC(=O)OC)C1=CC=CC=C1 Chemical compound [H]N(C(=O)CCCCCCC(=O)O)C1=CC=CC=C1.[H]N(C(=O)CCCCCCC(=O)OC)C1=CC=CC=C1 IJPNIXXQNJPMCA-UHFFFAOYSA-N 0.000 description 1
- OWDYDLVCUCFVDV-UHFFFAOYSA-N [H]N(CC1=CC=CC=C1)C(=O)CCCCCCC(=O)NO Chemical compound [H]N(CC1=CC=CC=C1)C(=O)CCCCCCC(=O)NO OWDYDLVCUCFVDV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/379,149 US20040072735A1 (en) | 2002-03-04 | 2003-03-04 | Methods of inducing terminal differentiation |
NZ55018503A NZ550185A (en) | 2002-03-04 | 2003-03-04 | Methods of inducing terminal differentiation Methods of inducing terminal differentiation |
US10/600,132 US7456219B2 (en) | 2002-03-04 | 2003-06-19 | Polymorphs of suberoylanilide hydroxamic acid |
US10/616,649 US7399787B2 (en) | 2002-03-04 | 2003-07-09 | Methods of treating cancer with HDAC inhibitors |
US10/650,025 US7148257B2 (en) | 2002-03-04 | 2003-08-26 | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
US10/665,079 US20040127523A1 (en) | 2002-03-04 | 2003-09-16 | Methods of treating cancer with HDAC inhibitors |
US10/692,523 US20040132825A1 (en) | 2002-03-04 | 2003-10-24 | Methods of treating cancer with HDAC inhibitors |
US10/567,952 US20070060614A1 (en) | 2002-03-04 | 2004-08-26 | Methods of treating cancer with hdac inhibitors |
US11/391,971 US7375137B2 (en) | 2002-03-04 | 2006-03-28 | Methods of treating cancer with HDAC inhibitors |
US11/492,478 US20060276547A1 (en) | 2002-03-04 | 2006-07-24 | Methods of treating cancer with HDAC inhibitors |
US11/853,700 US7732490B2 (en) | 2002-03-04 | 2007-09-11 | Methods of treating cancer |
US11/980,994 US20080227862A1 (en) | 2002-03-04 | 2007-10-30 | Methods of treating cancer with HDAC inhibitors |
US11/981,367 US7652069B2 (en) | 2002-03-04 | 2007-10-30 | Polymorphs of suberoylanilide hydroxamic acid |
US11/981,500 US20080249179A1 (en) | 2002-03-04 | 2007-10-30 | Methods of treating cancer with HDAC inhibitors |
US11/983,469 US20080114069A1 (en) | 2002-03-04 | 2007-11-09 | Methods of inducing terminal differentiation |
US12/077,415 US7847122B2 (en) | 2002-03-04 | 2008-03-18 | Polymorphs of suberoylanilide hydroxamic acid |
US12/077,396 US7851509B2 (en) | 2002-03-04 | 2008-03-18 | Polymorphs of suberoylanilide hydroxamic acid |
US12/653,073 US8101663B2 (en) | 2002-03-04 | 2009-12-07 | Polymorphs of suberoylanilide hydroxamic acid |
US12/799,368 US8067472B2 (en) | 2002-03-04 | 2010-04-23 | Methods of treating Hodgkin's and non-Hodgkin's lymphoma |
US13/276,710 US20120041067A1 (en) | 2002-03-04 | 2011-10-19 | Methods of Inducing Terminal Differentiation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36175902P | 2002-03-04 | 2002-03-04 | |
US10/379,149 US20040072735A1 (en) | 2002-03-04 | 2003-03-04 | Methods of inducing terminal differentiation |
Related Child Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/600,132 Continuation-In-Part US7456219B2 (en) | 2002-03-04 | 2003-06-19 | Polymorphs of suberoylanilide hydroxamic acid |
US10/616,649 Continuation-In-Part US7399787B2 (en) | 2002-03-04 | 2003-07-09 | Methods of treating cancer with HDAC inhibitors |
US10/650,025 Continuation-In-Part US7148257B2 (en) | 2002-03-04 | 2003-08-26 | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
US10/665,079 Continuation-In-Part US20040127523A1 (en) | 2002-03-04 | 2003-09-16 | Methods of treating cancer with HDAC inhibitors |
US10/692,523 Continuation-In-Part US20040132825A1 (en) | 2002-03-04 | 2003-10-24 | Methods of treating cancer with HDAC inhibitors |
US11/853,700 Continuation US7732490B2 (en) | 2002-03-04 | 2007-09-11 | Methods of treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040072735A1 true US20040072735A1 (en) | 2004-04-15 |
Family
ID=27805074
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/379,149 Abandoned US20040072735A1 (en) | 2002-03-04 | 2003-03-04 | Methods of inducing terminal differentiation |
US10/616,649 Active 2025-04-14 US7399787B2 (en) | 2002-03-04 | 2003-07-09 | Methods of treating cancer with HDAC inhibitors |
US10/665,079 Abandoned US20040127523A1 (en) | 2002-03-04 | 2003-09-16 | Methods of treating cancer with HDAC inhibitors |
US11/853,700 Active US7732490B2 (en) | 2002-03-04 | 2007-09-11 | Methods of treating cancer |
US11/983,469 Abandoned US20080114069A1 (en) | 2002-03-04 | 2007-11-09 | Methods of inducing terminal differentiation |
US12/799,368 Expired - Fee Related US8067472B2 (en) | 2002-03-04 | 2010-04-23 | Methods of treating Hodgkin's and non-Hodgkin's lymphoma |
US13/276,710 Abandoned US20120041067A1 (en) | 2002-03-04 | 2011-10-19 | Methods of Inducing Terminal Differentiation |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/616,649 Active 2025-04-14 US7399787B2 (en) | 2002-03-04 | 2003-07-09 | Methods of treating cancer with HDAC inhibitors |
US10/665,079 Abandoned US20040127523A1 (en) | 2002-03-04 | 2003-09-16 | Methods of treating cancer with HDAC inhibitors |
US11/853,700 Active US7732490B2 (en) | 2002-03-04 | 2007-09-11 | Methods of treating cancer |
US11/983,469 Abandoned US20080114069A1 (en) | 2002-03-04 | 2007-11-09 | Methods of inducing terminal differentiation |
US12/799,368 Expired - Fee Related US8067472B2 (en) | 2002-03-04 | 2010-04-23 | Methods of treating Hodgkin's and non-Hodgkin's lymphoma |
US13/276,710 Abandoned US20120041067A1 (en) | 2002-03-04 | 2011-10-19 | Methods of Inducing Terminal Differentiation |
Country Status (18)
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040018968A1 (en) * | 2002-04-15 | 2004-01-29 | George Sgouros | Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer |
US20040087631A1 (en) * | 2002-03-04 | 2004-05-06 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20040122101A1 (en) * | 2002-03-04 | 2004-06-24 | Miller Thomas A. | Polymorphs of suberoylanilide hydroxamic acid |
US20040127523A1 (en) * | 2002-03-04 | 2004-07-01 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20040254220A1 (en) * | 2003-03-17 | 2004-12-16 | Syrrx, Inc. | Histone deacetylase inhibitors |
US20050048847A1 (en) * | 2002-08-27 | 2005-03-03 | Guang-Rung Hsieh | Electrical power jack |
US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
US20050159470A1 (en) * | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
US20060009526A1 (en) * | 2002-02-15 | 2006-01-12 | Richon Victoria M | Method of treating TRX mediated diseases |
US20060079551A1 (en) * | 2001-10-16 | 2006-04-13 | Richon Victoria M | Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
US20060205941A1 (en) * | 2004-12-16 | 2006-09-14 | Bressi Jerome C | Histone deacetylase inhibitors |
US20060258694A1 (en) * | 2005-05-11 | 2006-11-16 | Bressi Jerome C | Histone deacetylase inhibitors |
US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US20070015809A1 (en) * | 2005-07-14 | 2007-01-18 | Bressi Jerome C | Histone deacetylase inhibitors |
US20070060614A1 (en) * | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
WO2007031853A2 (en) * | 2005-09-14 | 2007-03-22 | Nya Hamlet Pharma Ab | Therapeutic combination of hamlet and a hdac inhibitor to treat cancer |
WO2007056244A2 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of using saha and erlotinib for treating cancer |
US20070129290A1 (en) * | 2005-11-18 | 2007-06-07 | Or Yat S | Metabolite derivatives of the HDAC inhibitor FK228 |
US20070173527A1 (en) * | 2006-01-13 | 2007-07-26 | Bressi Jerome C | Histone deacetylase inhibitors |
US20070197473A1 (en) * | 2005-11-04 | 2007-08-23 | Frankel Stanley R | Methods of using SAHA and Bortezomib for treating cancer |
EP1833500A1 (en) * | 2004-12-14 | 2007-09-19 | Biorunx Co., Ltd | Method to enhance the bone formation activity of bmp by runx2 acetylation |
US20080124403A1 (en) * | 2006-06-08 | 2008-05-29 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
US20080132575A1 (en) * | 2005-05-20 | 2008-06-05 | Jeannie Chow Wong | Formulations Of Suberoylanilide Hydroxamic Acid And Methods For Producing Same |
US20080194690A1 (en) * | 2005-05-13 | 2008-08-14 | Topotarget Uk Limited | Pharmaceutical Formulations Of Hdac Inhibitors |
US20080202944A1 (en) * | 2005-04-22 | 2008-08-28 | Eduardo Santoli | Method for Use of an Electrochemical Sensor and Electrodes Forming Said Sensor |
US20080274120A1 (en) * | 2005-11-10 | 2008-11-06 | Topotarget Uk Limited | Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent |
US20090012175A1 (en) * | 2003-08-26 | 2009-01-08 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US20090186382A1 (en) * | 2006-12-29 | 2009-07-23 | Verdine Gregory L | Preparation of Romidepsin |
US20090215800A1 (en) * | 2005-05-05 | 2009-08-27 | Chroma Therapeutics Ltd | Enzyme and Receptor Modulation |
US20090305956A1 (en) * | 2006-04-24 | 2009-12-10 | Gloucester Pharmaceuticals, Inc. | Treatment of Ras-Expressing Tumors |
US20100093610A1 (en) * | 2006-12-29 | 2010-04-15 | Vrolijk Nicholas H | Romidepsin-based treatments for cancer |
US20100113392A1 (en) * | 2006-11-03 | 2010-05-06 | Badros Ashraf Z | Methods of using saha and bortezomib for treating multiple myeloma |
US20100113602A1 (en) * | 2007-02-27 | 2010-05-06 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Use of histone deacetylase inhibitors for the treatment of central nervous system metastases |
US20100190694A1 (en) * | 2009-01-14 | 2010-07-29 | Jan Fagerberg | Methods for identifying patients who will respond well to cancer treatment |
US20100286279A1 (en) * | 2007-09-25 | 2010-11-11 | Topotarget Uk Limited | Methods of Synthesis of Certain Hydroxamic Acid Compounds |
US20100317678A1 (en) * | 2006-10-30 | 2010-12-16 | Chroma Therapeutics Ltd. | Hydroxamates as inhibitors of histone deacetylase |
US20110003777A1 (en) * | 2008-03-07 | 2011-01-06 | Topotarget A/S | Methods of Treatment Employing Prolonged Continuous Infusion of Belinostat |
WO2012045804A1 (en) * | 2010-10-08 | 2012-04-12 | Vib Vzw | Hdac inhibitors to treat charcot-marie-tooth disease |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
US8980825B2 (en) | 2010-07-12 | 2015-03-17 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US9101579B2 (en) | 2012-11-14 | 2015-08-11 | Celgene Corporation | Inhibition of drug resistant cancer cells |
US9134325B2 (en) | 2012-09-07 | 2015-09-15 | Celgene Corporation | Resistance biomarkers for HDAC inhibitors |
US9463215B2 (en) | 2013-12-27 | 2016-10-11 | Celgene Corporation | Romidepsin formulations and uses thereof |
US10285959B2 (en) | 2005-02-03 | 2019-05-14 | Topotarget Uk Limited | Combination therapies using HDAC inhibitors |
US11583521B2 (en) * | 2020-07-01 | 2023-02-21 | Jubilant Pharma Holdings Inc. | Long-acting injection dosage form of beta 3 adrenoreceptor agonists |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6777217B1 (en) * | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US20030129724A1 (en) * | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
FR2847817B1 (fr) * | 2002-11-28 | 2006-11-10 | Centre Nat Rech Scient | Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires |
WO2004089293A2 (en) * | 2003-04-01 | 2004-10-21 | Memorial Sloan-Kettering Cancer Center | Hydroxamic acid compounds and methods of use thereof |
CA2532965C (en) | 2003-07-22 | 2013-05-14 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
KR20050022216A (ko) * | 2003-08-25 | 2005-03-07 | 윤덕구 | 동결건조 즉석소면 및 그 제조방법 |
CA2576667A1 (en) * | 2004-08-09 | 2006-02-16 | Astellas Pharma Inc. | Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac) |
WO2006077428A1 (en) * | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
US20080161251A1 (en) * | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Pharmaceutical Compounds |
US20080161355A1 (en) * | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents |
CA2937005A1 (en) | 2005-03-22 | 2006-09-28 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
WO2006113606A2 (en) * | 2005-04-18 | 2006-10-26 | Johns Hopkins University | Histone deacetylase inhibitors |
UA93355C2 (ru) * | 2005-05-20 | 2011-02-10 | Mepk Шарп Энд Доме Корп. | Композиция субероиланилид-гидроксаминовой кислоты и способы ee получения |
EP1937236A2 (en) * | 2005-09-07 | 2008-07-02 | Braincells, Inc. | Modulation of neurogenesis by hdac inhibition |
EP1940379A4 (en) * | 2005-09-30 | 2009-05-13 | Jackson H M Found Military Med | METHOD FOR THE TREATMENT OF HEMORRHAGIC SHOCKS AND ASSOCIATED DISEASES |
AU2006311829B8 (en) * | 2005-11-04 | 2013-02-21 | Merck Sharp & Dohme Corp. | Methods of treating cancers with SAHA, Carboplatin, and Paclitaxel and other combination therapies |
JP2009518394A (ja) * | 2005-12-05 | 2009-05-07 | アストラゼネカ・アクチエボラーグ | エソメプラゾールの非塩形態の新規の製造方法 |
US20070207950A1 (en) * | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
WO2008091349A1 (en) | 2006-02-14 | 2008-07-31 | The President And Fellows Of Harvard College | Bifunctional histone deacetylase inhibitors |
AU2007214458C1 (en) | 2006-02-14 | 2012-12-06 | Dana-Farber Cancer Institute, Inc. | Histone deacetylase inhibitors |
JP5497431B2 (ja) * | 2006-05-03 | 2014-05-21 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ヒストンデアセチラーゼおよびチューブリンデアセチラーゼ阻害剤 |
JP2009536186A (ja) * | 2006-05-08 | 2009-10-08 | アステックス・セラピューティクス・リミテッド | 癌処置のためのジアゾール誘導体の医薬組合せ |
US20100016435A1 (en) * | 2006-05-16 | 2010-01-21 | Mcgill University | Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties |
US20090239946A1 (en) * | 2006-09-28 | 2009-09-24 | Mckeown Arlene E | Pharmaceutical compositions of HDAC inhibitors and chelatable metal compounds, and metal-HDAC inhibitors chelate complexes |
RU2489429C2 (ru) * | 2007-12-20 | 2013-08-10 | Фарма Мар, С.А. | Противоопухолевые соединения |
CA2731730C (en) * | 2008-07-23 | 2017-06-13 | President And Fellows Of Harvard College | Deacetylase inhibitors and uses thereof |
WO2010043904A2 (en) | 2008-10-15 | 2010-04-22 | Generics [Uk] Limited | Improved process |
AU2009321384A1 (en) | 2008-11-26 | 2011-06-23 | Generics [Uk] Limited | Polymorphs |
US7994357B2 (en) * | 2009-04-03 | 2011-08-09 | Naturewise Biotech & Medicals Corporation | Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase |
ES2473792T3 (es) | 2009-04-03 | 2014-07-07 | Naturewise Biotech & Medicals Corporation | Compuestos cin�micos y derivados de los mismos para la inhibición de la histona desacetilasa |
EP2277387B1 (en) | 2009-07-22 | 2016-10-19 | NatureWise Biotech & Medicals Corporation | New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly |
WO2011019393A2 (en) | 2009-08-11 | 2011-02-17 | President And Fellows Of Harvard College | Class- and isoform-specific hdac inhibitors and uses thereof |
JP2013508458A (ja) | 2009-10-26 | 2013-03-07 | ラモット・アット・テル−アヴィヴ・ユニヴァーシティ・リミテッド | Ftsとhdac阻害剤との組合せを用いたがん治療 |
WO2011084623A1 (en) | 2009-12-16 | 2011-07-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment |
US8318641B2 (en) * | 2010-02-10 | 2012-11-27 | Selinfreund Richard H | Systems and methods for the detection of biomarkers |
WO2011127467A1 (en) * | 2010-04-09 | 2011-10-13 | Companion Diagnostics, Inc. | Devices, systems, and methods for biomarker stabilization |
WO2011140375A1 (en) | 2010-05-05 | 2011-11-10 | Diliberti Charles E | Methods of reducing symptoms in subjects using single dosage forms with tapering release rates |
US20120164674A1 (en) * | 2010-10-28 | 2012-06-28 | Selinfreund Richard H | Devices and washes for biomarker stabilization |
CN104185420B (zh) | 2011-11-30 | 2017-06-09 | 埃默里大学 | 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂 |
CN102793693A (zh) * | 2012-09-07 | 2012-11-28 | 天津医科大学 | 伏立诺他在制备治疗自身免疫及炎症性疾病药物方面的应用 |
CN105307683A (zh) | 2013-03-14 | 2016-02-03 | 基因泰克公司 | 治疗癌症和预防癌症药物抗性的方法 |
CN103819364B (zh) * | 2014-01-24 | 2015-12-02 | 中南大学 | N-烃酰基环内酰胺衍生物的一锅合成方法 |
JP6783247B2 (ja) | 2015-01-23 | 2020-11-11 | テンプル ユニヴァーシティ − オブ ザ コモンウェルス システム オブ ハイアー エデュケーション | ガン予防における短鎖脂肪酸の使用 |
WO2016164392A1 (en) | 2015-04-06 | 2016-10-13 | The Johns Hopkins University | A h3t3a mutant protein efficiently reduces h3t3p and causes increased cell death of rapidly dividing cells |
CN105055386A (zh) * | 2015-08-12 | 2015-11-18 | 天津医科大学总医院 | 伏立诺他用于制备免疫调节药物的应用 |
CN106187818B (zh) * | 2016-06-27 | 2017-12-08 | 刘美新 | 一种制备抗癌药物伏立诺他的方法 |
US11065217B2 (en) | 2017-01-27 | 2021-07-20 | Temple University—Of the Commonwealth System of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
BR112019021742A2 (pt) | 2017-04-17 | 2020-05-05 | Univ Chicago | composição, sistema, composição farmacêutica, composição alimentícia ou nutracêutica, método e uso da composição |
BR112022005595A2 (pt) | 2019-09-27 | 2022-07-19 | Takeda Pharmaceuticals Co | Composto, medicamento, métodos para inibir histona deacetilase 6 e para profilaxia ou tratamento de doença de alzheimer ou paralisia supranuclear progressiva em um mamífero, e, uso de composto |
Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4690918A (en) * | 1985-01-30 | 1987-09-01 | Teruhiko Beppu | Use of trichostatin compounds for treating tumor cells |
US5055608A (en) * | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
US5175191A (en) * | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5369108A (en) * | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5608108A (en) * | 1988-11-14 | 1997-03-04 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
US5654333A (en) * | 1991-10-21 | 1997-08-05 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for prevention of cancer using phenylacetic acids and derivatives thereof |
US5700811A (en) * | 1991-10-04 | 1997-12-23 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
US6239176B1 (en) * | 1997-03-11 | 2001-05-29 | Beacon Laboratories, Inc. | Uses of hydroxy and ether-containing oxyalkylene esters for treating metabolic conditions |
US6262116B1 (en) * | 1998-01-23 | 2001-07-17 | Sloan-Kettering Institute For Cancer Research | Transcription therapy for cancers |
US6495719B2 (en) * | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
US6511990B1 (en) * | 1999-09-08 | 2003-01-28 | Sloan-Kettering Institute For Cancer Research | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
US20030082666A1 (en) * | 2000-11-21 | 2003-05-01 | Kammer Gary M. | Method of treating autoimmune diseases |
US20030161830A1 (en) * | 2001-06-14 | 2003-08-28 | Jackson Donald G. | Novel human histone deacetylases |
US20030235588A1 (en) * | 2002-02-15 | 2003-12-25 | Richon Victoria M. | Method of treating TRX mediated diseases |
USRE38506E1 (en) * | 1991-10-04 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US20040087631A1 (en) * | 2002-03-04 | 2004-05-06 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20040122101A1 (en) * | 2002-03-04 | 2004-06-24 | Miller Thomas A. | Polymorphs of suberoylanilide hydroxamic acid |
US20040127522A1 (en) * | 2002-03-04 | 2004-07-01 | Chiao Judy H. | Methods of treating cancer with HDAC inhibitors |
US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20040132643A1 (en) * | 2002-01-09 | 2004-07-08 | Fojo Antonio Tito | Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms |
US20040167184A1 (en) * | 2001-03-27 | 2004-08-26 | Wiech Norbert L. | Treatment of lung cells with histone deacetylase inhibitors |
US20040266818A1 (en) * | 2003-04-01 | 2004-12-30 | Ronald Breslow | Hydroxamic acid compounds and methods of use thereof |
US20050004007A1 (en) * | 2000-09-12 | 2005-01-06 | Steven Grant | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents |
US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US20070060614A1 (en) * | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA622801A (en) | 1961-06-27 | L. Clark Robert | Substituted benzimidazolones | |
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
DE2460689C3 (de) * | 1974-12-20 | 1980-06-26 | Klinge Pharma Gmbh & Co, 8000 Muenchen | 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
JPS61251649A (ja) * | 1985-04-05 | 1986-11-08 | Mitsubishi Petrochem Co Ltd | ジカルボン酸ジアニリドの製造法 |
HU217629B (hu) | 1991-12-12 | 2000-03-28 | Novartis Ag. | Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására |
AU712801B2 (en) | 1995-09-20 | 1999-11-18 | Merck Sharp & Dohme Corp. | Histone deacetylase as target for antiprotozoal agents |
US6239178B1 (en) * | 1996-05-17 | 2001-05-29 | George Dimelow Alexander Lord | Method of treating mammals |
US6124495A (en) | 1997-03-11 | 2000-09-26 | Beacon Laboratories, Inc. | Unsaturated oxyalkylene esters and uses thereof |
US6030961A (en) | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
JPH10262694A (ja) | 1997-03-28 | 1998-10-06 | Sumitomo Forestry Co Ltd | B細胞性リンパ腫の骨髄転移検査法 |
US6387673B1 (en) | 1997-05-01 | 2002-05-14 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
AUPO721997A0 (en) | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
EA003862B1 (ru) | 1998-01-30 | 2003-10-30 | Байоджен, Инк. | Способ прекращения или замедления развития фолликулярной лимфомы и композиции для его осуществления |
AUPP505798A0 (en) | 1998-08-04 | 1998-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound fr225497 substance |
AU762079B2 (en) | 1998-09-25 | 2003-06-19 | Warner-Lambert Company | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin |
IL142531A0 (en) | 1998-10-13 | 2002-03-10 | Fujisawa Pharmaceutical Co | Cyclic peptide compound, processes for the preparation thereof and pharmaceutical compositions containing the same |
KR20020007398A (ko) | 1999-05-03 | 2002-01-26 | 추후제출 | 히스톤 탈아세틸화효소의 억제 |
US6450992B1 (en) | 1999-07-02 | 2002-09-17 | Smith & Nephew, Inc. | Cannula interface |
JP2001081031A (ja) | 1999-08-30 | 2001-03-27 | Schering Ag | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
US6673564B2 (en) | 1999-10-18 | 2004-01-06 | Millennium Pharmaceuticals, Inc. | Methods for using 22045, a human cyclic nucleotide phosphodiesterase |
US6541661B1 (en) | 1999-11-23 | 2003-04-01 | Methylgene, Inc. | Inhibitors of histone deacetylase |
EP1280764B1 (en) | 2000-03-24 | 2010-11-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
WO2002015921A2 (en) | 2000-08-18 | 2002-02-28 | The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
AU2001290131B2 (en) | 2000-09-29 | 2007-11-15 | Topotarget Uk Limited | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
AR035659A1 (es) | 2000-12-07 | 2004-06-23 | Hoffmann La Roche | Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos |
US6533803B2 (en) * | 2000-12-22 | 2003-03-18 | Advanced Medical Applications, Inc. | Wound treatment method and device with combination of ultrasound and laser energy |
WO2002060430A1 (en) * | 2001-02-01 | 2002-08-08 | Cornell Research Foundation, Inc. | Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors |
ITMI20011733A1 (it) | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
JP4638148B2 (ja) | 2001-10-16 | 2011-02-23 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 神経変性疾患および脳の癌の処置 |
EP1501489A4 (en) * | 2002-04-15 | 2007-11-21 | Sloan Kettering Inst Cancer | COMBINATION THERAPY FOR THE TREATMENT OF CANCER |
NZ560485A (en) | 2003-08-26 | 2009-03-31 | Merck Hdac Res Llc | Methods of treating cancer with HDAC inhibitors |
US20070190022A1 (en) * | 2003-08-29 | 2007-08-16 | Bacopoulos Nicholas G | Combination methods of treating cancer |
US20090227674A1 (en) | 2005-08-18 | 2009-09-10 | Richon Victoria M | Combination methods fo saha and targretin for treating cancer |
WO2007056244A2 (en) | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of using saha and erlotinib for treating cancer |
CN101299921A (zh) | 2005-11-04 | 2008-11-05 | 默克公司 | 用saha和硼替佐米治疗癌症的方法 |
AU2006311829B8 (en) | 2005-11-04 | 2013-02-21 | Merck Sharp & Dohme Corp. | Methods of treating cancers with SAHA, Carboplatin, and Paclitaxel and other combination therapies |
-
2003
- 2003-03-04 PL PL37223903A patent/PL372239A1/xx unknown
- 2003-03-04 ES ES09005103.8T patent/ES2532607T3/es not_active Expired - Lifetime
- 2003-03-04 IL IL16390903A patent/IL163909A0/xx unknown
- 2003-03-04 CA CA2671976A patent/CA2671976C/en not_active Expired - Lifetime
- 2003-03-04 EP EP03711372A patent/EP1487426B1/en not_active Revoked
- 2003-03-04 WO PCT/US2003/006451 patent/WO2003075839A2/en active IP Right Grant
- 2003-03-04 CN CN2008100838935A patent/CN101259120B/zh not_active Expired - Lifetime
- 2003-03-04 CN CNA038095890A patent/CN1720034A/zh active Pending
- 2003-03-04 NZ NZ567758A patent/NZ567758A/en not_active IP Right Cessation
- 2003-03-04 NZ NZ535578A patent/NZ535578A/en not_active IP Right Cessation
- 2003-03-04 AU AU2003213684A patent/AU2003213684C1/en active Active
- 2003-03-04 CA CA 2632078 patent/CA2632078C/en not_active Expired - Lifetime
- 2003-03-04 MX MXPA04008577A patent/MXPA04008577A/es active IP Right Grant
- 2003-03-04 KR KR1020087010088A patent/KR100892016B1/ko active IP Right Grant
- 2003-03-04 US US10/379,149 patent/US20040072735A1/en not_active Abandoned
- 2003-03-04 CN CN2013102683183A patent/CN103393630A/zh active Pending
- 2003-03-04 KR KR1020077003262A patent/KR100868813B1/ko active IP Right Grant
- 2003-03-04 EP EP20100184834 patent/EP2266552A3/en not_active Withdrawn
- 2003-03-04 BR BR0308250A patent/BR0308250A/pt not_active Application Discontinuation
- 2003-03-04 EP EP20090005103 patent/EP2082737B1/en not_active Expired - Lifetime
- 2003-03-04 EP EP20100183586 patent/EP2322160A1/en not_active Withdrawn
- 2003-03-04 JP JP2003574115A patent/JP4732693B2/ja not_active Expired - Lifetime
- 2003-03-04 RU RU2007112879A patent/RU2394022C2/ru active
- 2003-03-04 NZ NZ55018503A patent/NZ550185A/xx not_active IP Right Cessation
- 2003-03-04 CA CA 2478094 patent/CA2478094C/en not_active Expired - Lifetime
- 2003-03-04 RU RU2004133675A patent/RU2320331C2/ru active Protection Beyond IP Right Term
- 2003-07-09 US US10/616,649 patent/US7399787B2/en active Active
- 2003-09-16 US US10/665,079 patent/US20040127523A1/en not_active Abandoned
-
2004
- 2004-03-01 ZA ZA200407942A patent/ZA200407942B/xx unknown
- 2004-09-05 IL IL16390904A patent/IL163909A/en not_active IP Right Cessation
- 2004-09-28 NO NO20044112A patent/NO329984B1/no not_active IP Right Cessation
-
2005
- 2005-05-25 HK HK05104380A patent/HK1072362A1/xx not_active IP Right Cessation
-
2006
- 2006-02-23 ZA ZA200601757A patent/ZA200601757B/en unknown
-
2007
- 2007-09-11 US US11/853,700 patent/US7732490B2/en active Active
- 2007-11-09 US US11/983,469 patent/US20080114069A1/en not_active Abandoned
-
2009
- 2009-03-12 IL IL197582A patent/IL197582A/en active IP Right Grant
- 2009-07-20 NO NO20092714A patent/NO332749B1/no not_active IP Right Cessation
- 2009-08-17 JP JP2009188710A patent/JP5586896B2/ja not_active Expired - Lifetime
- 2009-08-17 JP JP2009188712A patent/JP5675071B2/ja not_active Expired - Lifetime
-
2010
- 2010-03-09 RU RU2010108448/15A patent/RU2530648C2/ru active
- 2010-04-23 US US12/799,368 patent/US8067472B2/en not_active Expired - Fee Related
-
2011
- 2011-10-19 US US13/276,710 patent/US20120041067A1/en not_active Abandoned
-
2014
- 2014-07-17 JP JP2014146512A patent/JP2014237669A/ja active Pending
Patent Citations (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4690918A (en) * | 1985-01-30 | 1987-09-01 | Teruhiko Beppu | Use of trichostatin compounds for treating tumor cells |
US5773474A (en) * | 1988-11-14 | 1998-06-30 | The Trustees Of Columbia University In The City Of New York And Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
US5055608A (en) * | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
US5175191A (en) * | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5608108A (en) * | 1988-11-14 | 1997-03-04 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
US5932616A (en) * | 1991-10-04 | 1999-08-03 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5700811A (en) * | 1991-10-04 | 1997-12-23 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
US6087367A (en) * | 1991-10-04 | 2000-07-11 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5369108A (en) * | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
USRE38506E1 (en) * | 1991-10-04 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5654333A (en) * | 1991-10-21 | 1997-08-05 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for prevention of cancer using phenylacetic acids and derivatives thereof |
US6239176B1 (en) * | 1997-03-11 | 2001-05-29 | Beacon Laboratories, Inc. | Uses of hydroxy and ether-containing oxyalkylene esters for treating metabolic conditions |
US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
US6451334B2 (en) * | 1997-05-30 | 2002-09-17 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
US6262116B1 (en) * | 1998-01-23 | 2001-07-17 | Sloan-Kettering Institute For Cancer Research | Transcription therapy for cancers |
US20040002506A1 (en) * | 1999-09-08 | 2004-01-01 | Sloan Kettering Institute For Cancer Research | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
US6511990B1 (en) * | 1999-09-08 | 2003-01-28 | Sloan-Kettering Institute For Cancer Research | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
US20050004007A1 (en) * | 2000-09-12 | 2005-01-06 | Steven Grant | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents |
US20030082666A1 (en) * | 2000-11-21 | 2003-05-01 | Kammer Gary M. | Method of treating autoimmune diseases |
US20030114525A1 (en) * | 2000-11-21 | 2003-06-19 | Kammer Gary M. | Method of treating autoimmune diseases |
US20040167184A1 (en) * | 2001-03-27 | 2004-08-26 | Wiech Norbert L. | Treatment of lung cells with histone deacetylase inhibitors |
US6495719B2 (en) * | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
US20030161830A1 (en) * | 2001-06-14 | 2003-08-28 | Jackson Donald G. | Novel human histone deacetylases |
US20040132643A1 (en) * | 2002-01-09 | 2004-07-08 | Fojo Antonio Tito | Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms |
US20030235588A1 (en) * | 2002-02-15 | 2003-12-25 | Richon Victoria M. | Method of treating TRX mediated diseases |
US20040127523A1 (en) * | 2002-03-04 | 2004-07-01 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20040127522A1 (en) * | 2002-03-04 | 2004-07-01 | Chiao Judy H. | Methods of treating cancer with HDAC inhibitors |
US20040122101A1 (en) * | 2002-03-04 | 2004-06-24 | Miller Thomas A. | Polymorphs of suberoylanilide hydroxamic acid |
US20040087631A1 (en) * | 2002-03-04 | 2004-05-06 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20060167103A1 (en) * | 2002-03-04 | 2006-07-27 | Aton Pharma, Inc. | Methods of treating cancer with HDAC inhibitors |
US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US20070060614A1 (en) * | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
US20040266818A1 (en) * | 2003-04-01 | 2004-12-30 | Ronald Breslow | Hydroxamic acid compounds and methods of use thereof |
Cited By (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110124731A1 (en) * | 2001-10-16 | 2011-05-26 | Sloan-Kettering Institute For Cancer Research | Treatment Of Neurodegenerative Diseases And Cancer Of The Brain Using Histone Deacetylase Inhibitors |
US7879865B2 (en) | 2001-10-16 | 2011-02-01 | Sloan-Kettering Institute For Cancer Research | Treatment of cancer of the brain using histone deacetylase inhibitors |
US20060079551A1 (en) * | 2001-10-16 | 2006-04-13 | Richon Victoria M | Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
US20060009526A1 (en) * | 2002-02-15 | 2006-01-12 | Richon Victoria M | Method of treating TRX mediated diseases |
US20060009527A1 (en) * | 2002-02-15 | 2006-01-12 | Richon Victoria M | Method of treating TRX mediated diseases |
US20080194692A1 (en) * | 2002-03-04 | 2008-08-14 | Miller Thomas A | Polymorphs of suberoylanilide hydroxamic acid |
US7652069B2 (en) | 2002-03-04 | 2010-01-26 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
US8101663B2 (en) | 2002-03-04 | 2012-01-24 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
US20040087631A1 (en) * | 2002-03-04 | 2004-05-06 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
US20080249179A1 (en) * | 2002-03-04 | 2008-10-09 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20040127522A1 (en) * | 2002-03-04 | 2004-07-01 | Chiao Judy H. | Methods of treating cancer with HDAC inhibitors |
US20040127523A1 (en) * | 2002-03-04 | 2004-07-01 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20080228005A1 (en) * | 2002-03-04 | 2008-09-18 | Miller Thomas A | Polymorphs of suberoylanilide hydroxamic acid |
US8067472B2 (en) | 2002-03-04 | 2011-11-29 | Merck Hdac Research, Llc | Methods of treating Hodgkin's and non-Hodgkin's lymphoma |
US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
US20100168242A1 (en) * | 2002-03-04 | 2010-07-01 | Miller Thomas A | Polymorphs of suberoylanilide hydroxamic acid |
US7399787B2 (en) | 2002-03-04 | 2008-07-15 | Merck Hdac Research, Llc | Methods of treating cancer with HDAC inhibitors |
US7732490B2 (en) | 2002-03-04 | 2010-06-08 | Merck Hdac Research, Llc | Methods of treating cancer |
US7847122B2 (en) | 2002-03-04 | 2010-12-07 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
US20040122101A1 (en) * | 2002-03-04 | 2004-06-24 | Miller Thomas A. | Polymorphs of suberoylanilide hydroxamic acid |
US20080119562A1 (en) * | 2002-03-04 | 2008-05-22 | Richon Victoria M | Methods of Inducing Terminal Differentiation |
US7851509B2 (en) | 2002-03-04 | 2010-12-14 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
US7375137B2 (en) | 2002-03-04 | 2008-05-20 | Merck Hdac Research, Llc | Methods of treating cancer with HDAC inhibitors |
US20100210729A1 (en) * | 2002-03-04 | 2010-08-19 | Richon Victoria M | Methods of inducing terminal differentiation |
US20070060614A1 (en) * | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
US20080114069A1 (en) * | 2002-03-04 | 2008-05-15 | Richon Victoria M | Methods of inducing terminal differentiation |
US20040018968A1 (en) * | 2002-04-15 | 2004-01-29 | George Sgouros | Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer |
US20050048847A1 (en) * | 2002-08-27 | 2005-03-03 | Guang-Rung Hsieh | Electrical power jack |
US20040254220A1 (en) * | 2003-03-17 | 2004-12-16 | Syrrx, Inc. | Histone deacetylase inhibitors |
US20050137232A1 (en) * | 2003-03-17 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
US20090012175A1 (en) * | 2003-08-26 | 2009-01-08 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
US20050159470A1 (en) * | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
EP1833500A4 (en) * | 2004-12-14 | 2009-08-12 | Biorunx Co Ltd | METHOD FOR REINFORCING BONE-MAKING ACTIVITY OF BMP BY RUNX2 ACETYLATION |
EP1833500A1 (en) * | 2004-12-14 | 2007-09-19 | Biorunx Co., Ltd | Method to enhance the bone formation activity of bmp by runx2 acetylation |
US20060205941A1 (en) * | 2004-12-16 | 2006-09-14 | Bressi Jerome C | Histone deacetylase inhibitors |
US10799469B2 (en) | 2005-02-03 | 2020-10-13 | Topotarget Uk Limited | Combination therapies using HDAC inhibitors |
US10285959B2 (en) | 2005-02-03 | 2019-05-14 | Topotarget Uk Limited | Combination therapies using HDAC inhibitors |
US20080202944A1 (en) * | 2005-04-22 | 2008-08-28 | Eduardo Santoli | Method for Use of an Electrochemical Sensor and Electrodes Forming Said Sensor |
US20090215800A1 (en) * | 2005-05-05 | 2009-08-27 | Chroma Therapeutics Ltd | Enzyme and Receptor Modulation |
US20060258694A1 (en) * | 2005-05-11 | 2006-11-16 | Bressi Jerome C | Histone deacetylase inhibitors |
US9957227B2 (en) | 2005-05-13 | 2018-05-01 | Topotarget Uk Limited | Pharmaceutical formulations of HDAC inhibitors |
US8835501B2 (en) | 2005-05-13 | 2014-09-16 | Topotarget Uk Limited | Pharmaceutical formulations of HDAC inhibitors |
US9856211B2 (en) | 2005-05-13 | 2018-01-02 | Topotarget Uk Limited | Pharmaceutical formulations of HDAC inhibitors |
US20080194690A1 (en) * | 2005-05-13 | 2008-08-14 | Topotarget Uk Limited | Pharmaceutical Formulations Of Hdac Inhibitors |
US20100119596A1 (en) * | 2005-05-20 | 2010-05-13 | Jeannie Chow Wong | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
US20080132575A1 (en) * | 2005-05-20 | 2008-06-05 | Jeannie Chow Wong | Formulations Of Suberoylanilide Hydroxamic Acid And Methods For Producing Same |
US8450372B2 (en) | 2005-05-20 | 2013-05-28 | Merck Sharp & Dohme Corp. | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
US8093295B2 (en) | 2005-05-20 | 2012-01-10 | Merck Sharp & Dohme Corp. | Formulations of suberoylanilide hydroxamic acid and methods for producing the same |
US8288440B2 (en) | 2005-05-20 | 2012-10-16 | Merck Sharp & Dohme Corp. | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
US20080114037A1 (en) * | 2005-07-14 | 2008-05-15 | Bressi Jerome C | Histone deacetylase inhibitors |
US20090111996A1 (en) * | 2005-07-14 | 2009-04-30 | Bressi Jerome C | Histone deacetylase inhibitors |
US20080119648A1 (en) * | 2005-07-14 | 2008-05-22 | Bressi Jerome C | Histone deacetylase inhibitors |
US20080119658A1 (en) * | 2005-07-14 | 2008-05-22 | Bressi Jerome C | Histone deacetylase inhibitors |
US20080108829A1 (en) * | 2005-07-14 | 2008-05-08 | Bressi Jerome C | Histone deacetylase inhibitors |
US7732475B2 (en) | 2005-07-14 | 2010-06-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7741494B2 (en) | 2005-07-14 | 2010-06-22 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US20070015809A1 (en) * | 2005-07-14 | 2007-01-18 | Bressi Jerome C | Histone deacetylase inhibitors |
US20090036368A1 (en) * | 2005-09-14 | 2009-02-05 | Hamlet Pharma Ab | Therapeutic Combination |
WO2007031853A3 (en) * | 2005-09-14 | 2007-05-18 | Hamlet Pharma Ab | Therapeutic combination of hamlet and a hdac inhibitor to treat cancer |
WO2007031853A2 (en) * | 2005-09-14 | 2007-03-22 | Nya Hamlet Pharma Ab | Therapeutic combination of hamlet and a hdac inhibitor to treat cancer |
US20070197473A1 (en) * | 2005-11-04 | 2007-08-23 | Frankel Stanley R | Methods of using SAHA and Bortezomib for treating cancer |
WO2007056244A2 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of using saha and erlotinib for treating cancer |
US20070197568A1 (en) * | 2005-11-04 | 2007-08-23 | Paul Bunn | Methods of using SAHA and Erlotinib for treating cancer |
US20090247549A1 (en) * | 2005-11-04 | 2009-10-01 | Frankel Stanley R | Methods of using saha and bortezomib for treating cancer |
WO2007056244A3 (en) * | 2005-11-04 | 2007-09-07 | Merck & Co Inc | Methods of using saha and erlotinib for treating cancer |
US20080274120A1 (en) * | 2005-11-10 | 2008-11-06 | Topotarget Uk Limited | Histone Deacetylase (Hdac) Inhibitors (Pxd101) for the Treatment of Cancer Alone or in Combination With Chemotherapeutic Agent |
US9603926B2 (en) | 2005-11-10 | 2017-03-28 | Topotarget Uk Limited | Histone deacetylase (HDAC) inhibitors for the treatment of cancer |
US8828392B2 (en) | 2005-11-10 | 2014-09-09 | Topotarget Uk Limited | Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent |
US20070129290A1 (en) * | 2005-11-18 | 2007-06-07 | Or Yat S | Metabolite derivatives of the HDAC inhibitor FK228 |
US20070173527A1 (en) * | 2006-01-13 | 2007-07-26 | Bressi Jerome C | Histone deacetylase inhibitors |
US9539303B2 (en) | 2006-04-24 | 2017-01-10 | Celgene Corporation | Treatment of Ras-expressing tumors |
US20090305956A1 (en) * | 2006-04-24 | 2009-12-10 | Gloucester Pharmaceuticals, Inc. | Treatment of Ras-Expressing Tumors |
US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
US20080124403A1 (en) * | 2006-06-08 | 2008-05-29 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
US9259452B2 (en) | 2006-06-08 | 2016-02-16 | Gelgene Corporation | Deacetylase inhibitor therapy |
US8962825B2 (en) | 2006-10-30 | 2015-02-24 | Glaxosmithkline Intellectual Property Development Limited | Hydroxamates as inhibitors of histone deacetylase |
US20100317678A1 (en) * | 2006-10-30 | 2010-12-16 | Chroma Therapeutics Ltd. | Hydroxamates as inhibitors of histone deacetylase |
US20100113392A1 (en) * | 2006-11-03 | 2010-05-06 | Badros Ashraf Z | Methods of using saha and bortezomib for treating multiple myeloma |
US20090186382A1 (en) * | 2006-12-29 | 2009-07-23 | Verdine Gregory L | Preparation of Romidepsin |
US20090209616A1 (en) * | 2006-12-29 | 2009-08-20 | Verdine Gregory L | Preparation of romidepsin |
US20100093610A1 (en) * | 2006-12-29 | 2010-04-15 | Vrolijk Nicholas H | Romidepsin-based treatments for cancer |
US8691534B2 (en) | 2006-12-29 | 2014-04-08 | Celgene Corporation | Preparation of romidepsin |
US20100113602A1 (en) * | 2007-02-27 | 2010-05-06 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Use of histone deacetylase inhibitors for the treatment of central nervous system metastases |
US20100286279A1 (en) * | 2007-09-25 | 2010-11-11 | Topotarget Uk Limited | Methods of Synthesis of Certain Hydroxamic Acid Compounds |
US8642809B2 (en) | 2007-09-25 | 2014-02-04 | Topotarget Uk Ltd. | Methods of synthesis of certain hydroxamic acid compounds |
US20110003777A1 (en) * | 2008-03-07 | 2011-01-06 | Topotarget A/S | Methods of Treatment Employing Prolonged Continuous Infusion of Belinostat |
US20100190694A1 (en) * | 2009-01-14 | 2010-07-29 | Jan Fagerberg | Methods for identifying patients who will respond well to cancer treatment |
US8980825B2 (en) | 2010-07-12 | 2015-03-17 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US9624271B2 (en) | 2010-07-12 | 2017-04-18 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US9518094B2 (en) | 2010-07-12 | 2016-12-13 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
AU2011311531B2 (en) * | 2010-10-08 | 2014-11-20 | Life Sciences Research Partners Vzw | HDAC inhibitors to treat Charcot-Marie-Tooth disease |
US9238028B2 (en) * | 2010-10-08 | 2016-01-19 | Vib Vzw | HDAC inhibitors to treat charcot-marie-tooth disease |
WO2012045804A1 (en) * | 2010-10-08 | 2012-04-12 | Vib Vzw | Hdac inhibitors to treat charcot-marie-tooth disease |
US9134325B2 (en) | 2012-09-07 | 2015-09-15 | Celgene Corporation | Resistance biomarkers for HDAC inhibitors |
US9101579B2 (en) | 2012-11-14 | 2015-08-11 | Celgene Corporation | Inhibition of drug resistant cancer cells |
US9468664B2 (en) | 2013-12-27 | 2016-10-18 | Celgene Corporation | Romidepsin formulations and uses thereof |
US9463215B2 (en) | 2013-12-27 | 2016-10-11 | Celgene Corporation | Romidepsin formulations and uses thereof |
US9782451B2 (en) | 2013-12-27 | 2017-10-10 | Celgene Corporation | Romidepsin formulations and uses thereof |
US9795650B2 (en) | 2013-12-27 | 2017-10-24 | Celgene Corporation | Romidepsin formulations and uses thereof |
US11583521B2 (en) * | 2020-07-01 | 2023-02-21 | Jubilant Pharma Holdings Inc. | Long-acting injection dosage form of beta 3 adrenoreceptor agonists |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7732490B2 (en) | Methods of treating cancer | |
US7375137B2 (en) | Methods of treating cancer with HDAC inhibitors | |
US8101663B2 (en) | Polymorphs of suberoylanilide hydroxamic acid | |
US20090012175A1 (en) | Methods of treating cancer with HDAC inhibitors | |
Richon et al. | Methods of treating Hodgkin's and non-Hodgkin's lymphoma | |
AU2007203525C1 (en) | Methods of Inducing Terminal Differentiation | |
KR20050020760A (ko) | 말단 분화의 유도 방법 | |
NZ568678A (en) | Methods of inducing terminal differentiation using suberoylanilide hydroxamic acid (SAHA) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MERCK HDAC RESEARCH, LLC, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ATON PHARMA, INC.;REEL/FRAME:018312/0647 Effective date: 20060828 |
|
AS | Assignment |
Owner name: ATON PHARMA, INC. (A SUBSIDIARY OF MERCK & CO., IN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHIAO, JUDY H.;MILLER, THOMAS A.;RICHON, VICTORIA M.;REEL/FRAME:018651/0928;SIGNING DATES FROM 20060809 TO 20060821 Owner name: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, NEW Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RICHON, VICTORIA M.;KELLY, W. KEVIN;REEL/FRAME:018651/0990;SIGNING DATES FROM 20060809 TO 20061023 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:SLOAN-KETTERING INSTITUTE FOR CANCER RES;REEL/FRAME:022451/0708 Effective date: 20090323 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:SLOAN-KETTERING INSTITUTE FOR CANCER RES;REEL/FRAME:024851/0340 Effective date: 20090323 |